Controversies in cardiology 2 - Controversies in hypertension

被引:101
作者
Kaplan, NM
Opie, LH [1 ]
机构
[1] Univ Cape Town, Sch Med, Hatter Inst Heart Res, Cape Heart Ctr, ZA-7925 Cape Town, South Africa
[2] Univ Texas, SW Med Ctr, Dallas, TX USA
[3] Univ Cape Town, Sch Med, Dept Med, ZA-7925 Cape Town, South Africa
关键词
D O I
10.1016/S0140-6736(06)67965-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertension remains the most common risk factor for cardiovascular morbidity and mortality. Its incidence is rising in both ageing and obese populations, but its control remains inadequate worldwide. We address several persisting controversies that may interfere with appropriate management of hypertension. They include: the reasons behind the increasing incidence of hypertension and the possible ways to slow the process, especially by lifestyle changes; the need for overall cardiovascular risk assessment; the major issues in the decision to institute drug therapy and the choice of drugs; and the importance of screening for various identifiable causes. We provide the background for these controversies, followed by some opinions on how to guide practitioners to offer more effective management of hypertension.
引用
收藏
页码:168 / 176
页数:9
相关论文
共 67 条
[21]   Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland clinic experience [J].
Hamrahian, AH ;
Ioachimescu, AG ;
Remer, EM ;
Motta-Ramirez, G ;
Bogabathina, H ;
Levin, HS ;
Reddy, S ;
Gill, IS ;
Siperstein, A ;
Bravo, EL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (02) :871-877
[22]   Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health [J].
He, F ;
MacGregor, GA .
JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (11) :761-770
[23]   Modest salt reduction lowers blood pressure in isolated systolic hypertension and combined hypertension [J].
He, FJ ;
Markandu, ND ;
MacGregor, GA .
HYPERTENSION, 2005, 46 (01) :66-70
[24]  
Jackson R, 2005, LANCET, V365, P434, DOI 10.1016/S0140-6736(05)17833-7
[25]   Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? [J].
Johnson, RJ ;
Kang, DH ;
Feig, D ;
Kivlighn, S ;
Kanellis, J ;
Watanabe, S ;
Tuttle, KR ;
Rodriguez-Iturbe, B ;
Herrera-Acosta, J ;
Mazzali, M .
HYPERTENSION, 2003, 41 (06) :1183-1190
[26]   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].
Julius, S ;
Kjeldsen, SE ;
Weber, M ;
Brunner, HR ;
Ekman, S ;
Hansson, L ;
Hua, TS ;
Laragh, J ;
McInnes, GT ;
Mitchell, L ;
Plat, F ;
Schork, A ;
Smith, B ;
Zanchetti, A .
LANCET, 2004, 363 (9426) :2022-2031
[27]  
Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3
[28]  
Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
[29]  
Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
[30]   Angiotensin receptor blockers and myocardial infarction - Results reflect different cardiovascular states in patients with types 1 and 2 diabetes [J].
Lewis, EJ .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7502) :1269-+